.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,601,730

« Back to Dashboard

Claims for Patent: 7,601,730

Title:Carboxylic acid derivatives, their preparation and use
Abstract:Carboxylic acid derivatives ##STR00001## where R--R.sup.6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
Inventor(s): Riechers; Hartmut (Neustadt, DE), Klinge; Dagmar (Heidelberg, DE), Amberg; Wilhelm (Friedrichsdorf, DE), Kling; Andreas (Mannheim, DE), Muller; Stefan (Speyer, DE), Baumann; Ernst (Dudenhofen, DE), Rheinheimer; Joachim (Ludwigshafen, DE), Vogelbacher; Uwe Josef (Ludwigshafen, DE), Wernet; Wolfgang (Hassloch, DE), Unger; Liliane (Ludwigshafen, DE), Raschack; Manfred (Weisenheim, DE)
Assignee: Abbott GmbH & Co. KG (Wiesbaden, DE)
Application Number:11/502,293
Patent Claims: 1. A method to treat a disease in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound, or a salt thereof having the formula ##STR00016## wherein: X is CH; Y is oxygen; Z is oxygen; R is CO.sub.2H; R.sup.2 is methyl; R.sup.3 is methyl; R.sup.4 is phenyl; R.sup.5 is phenyl; and R.sup.6 is methyl, or an enantiomer thereof; wherein said disease is selected from the group consisting of hypertension, pulmonary hypertension, myocardial infarction, angina pectoris, acute kidney failure, renal insufficiency, cerebral vasospasms, cerebral ischemia, subarachnoid hemorrhages, asthma, atherosclerosis, intravascular coagulation, restenosis after angioplasty, hypertension caused by ischemia or intoxication, kidney failure caused by ischemia or intoxication, Raynaud's syndrome, and asthmatic airway condition.

2. A method to treat a disease in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound, or a salt thereof, having the formula ##STR00017## wherein: X is CH; Y is oxygen; Z is oxygen; R is CO.sub.2H; R.sup.2 is methyl; R.sup.3 is methyl; R.sup.4 is phenyl; R.sup.5 is phenyl; and R.sup.6 is methyl, or an enantiomer thereof; wherein said disease is hypertension.

3. A method to treat a disease in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound, or a salt thereof, having the formula ##STR00018## wherein: X is CH; Y is oxygen; Z is oxygen; R is CO.sub.2H; R.sup.2 is methyl; R.sup.3 is methyl; R.sup.4 is phenyl; R.sup.5 is phenyl; and R.sup.6 is methyl, or an enantiomer thereof; wherein said disease is pulmonary hypertension.

4. The method of claim 1, wherein said compound is an enantiomerically-pure form.

5. The method of claim 1, further characterized by administering said compound orally or parenterally.

6. The method of claim 5, wherein said compound is administered orally in a daily dose of about 0.5 mg/kg to about 50 mg/kg of body weight.

7. The method of claim 5, wherein said compound is administered parenterally in a daily dose of about 0.1 mg/kg to about 10 mg/kg of body weight.

8. The method of claim 5, wherein said compound is in solid or liquid pharmaceutical form.

9. The method of claim 5, wherein said compound is orally administered with vapor or spray means through nasopharyngeal space.

10. The method of claim 5, wherein said compound is parenterally administered by subcutaneous, intravenous, intramuscular or intraperitoneal means.

11. The method of claim 1, wherein said compound is an optically active enantiomer.

12. The method of claim 11, wherein the enantiomer is the (S)-enantiomer.

13. The method of claim 12, wherein the enantiomer is pure form of the (S)-enantiomer.

14. The method of claim 11, wherein the enantiomer is the (R)-enantiomer.

15. The method of claim 14, wherein the enantiomer is pure form of (R)-enantiomer.

16. The method of claim 1, wherein said compound is a racemate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc